{"transactions":[{"id":1603654,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T17:44:26.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":72000,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001610717-24-000124","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000124/form4.xml","form_type":"4"}},{"id":1612706,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":16428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":16428,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":16428},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612705,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":65713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date."}],"balance_after":65713,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":65713},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612704,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":75183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":75183,"derivative":{"exercise_price":0.96,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":75183},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612703,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2025-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612702,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2022-03-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":92000},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612701,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":255626,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":16.18,"exercise_date":"2021-01-01","expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":255626},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1783144,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T16:08:45.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001610717-23-000277","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071723000277/form4.xml","form_type":"4"}},{"id":1947672,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T16:12:14.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001567619-23-005257","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000156761923005257/doc1.xml","form_type":"4"}},{"id":2209292,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T16:15:52.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":46000,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001567619-22-013870","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000156761922013870/doc1.xml","form_type":"4"}}]}